학술논문
PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESS
Document Type
Academic Journal
Author
Source
The Journal of Urology. June, 2004, Vol. 171 Issue 6, p2245, 5 p.
Subject
Language
English
ISSN
0022-5347
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1097/01.ju.0000127731.56103.50 Byline: RENE RAAIJMAKERS, BERT G. BLIJENBERG, JUDITH A. FINLAY, HARRY G. RITTENHOUSE, MARK F. WILDHAGEN, MONIQUE J. ROOBOL, FRITZ H. SCHRADER Keywords: prostate; prostatic neoplasms; prostate-specific antigen; mass screening; biopsy Abstract: We evaluated the positive predictive value and cancer detection rate in the prostate specific antigen (PSA) range of 2.0 to 3.9 ng/ml and assessed the value of percent free (F) PSA (FPSA) on tumor detection and tumor aggressiveness in this low PSA range. Author Affiliation: From the Departments of Urology (RR, MFW, MJR, FHS) and Clinical Chemistry (BGB), Erasmus MC, Rotterdam, The Netherlands, and Hybritech, Inc., a subsidiary of Beckman Coulter, Inc. (JAF, HGR), San Diego, California Article History: Accepted 16 January 2004 Article Note: (footnote) Study received Dutch law on population screening approval. Supported by Grants EUR-94-869 and EUR-98-1757 from the Dutch Cancer Society, Grants 002-22820 and 2000-2-1016 from The Netherlands Organization for Health Research and Development (ZONMw), 5th Framework Program Grant QLRI-2000-01741 from the European Union, Europe Against Cancer and a grant from Hybritech, Inc., a subsidiary of Beckman Coulter, Inc.